Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 412,284 | 0 | 0 | N/A | 0 |
| Marketable Securities | 97,281 | 0 | 0 | N/A | 0 |
| TOTAL | $525,735 | $0 | $0 | $N/A | $0 |
| Non-Current Assets | |||||
| PPE Net | 1,934 | N/A | N/A | N/A | N/A |
| Investments And Advances | 9,913 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7,167 | 0 | 0 | 0 | 0 |
| TOTAL | $19,014 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $544,749 | $0 | $0 | $N/A | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,229 | 0 | 0 | 0 | 0 |
| Accrued Expenses | 23,347 | 0 | 0 | N/A | 0 |
| Other current liabilities | 149 | 0 | 0 | N/A | 0 |
| TOTAL | $29,123 | $0 | $0 | $N/A | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,933 | 0 | 0 | 0 | 0 |
| TOTAL | $2,933 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $32,056 | $0 | $0 | $N/A | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 152,703 | N/A | N/A | N/A | N/A |
| Common Shares | 15 | 0 | 0 | N/A | 0 |
| Retained earnings | -594,704 | 0 | 0 | N/A | 0 |
| Other shareholders' equity | -311 | 0 | 0 | 0 | 0 |
| TOTAL | $512,693 | $0 | $0 | $N/A | $0 |
| Total Liabilities And Equity | $544,749 | $0 | $0 | $0 | $0 |